Thrombogenics N.V. | Mutual Funds
Mutual Funds that own Thrombogenics N.V.
Government Pension Fund - Global (The)
321,244
0.84%
-163,896
0%
12/31/2017
DFA Continental Small Company Series
205,315
0.54%
21,614
0.03%
01/31/2018
UniSector: BioPharma
165,273
0.43%
-78,125
0.41%
03/31/2018
BNP Paribas B - Pension Balanced
144,929
0.38%
0
0.03%
09/29/2017
NFU Mutual OEIC - Global Growth Fund
144,912
0.38%
0
0.56%
06/30/2017
DFA International Core Equity Portfolio
139,163
0.36%
20,839
0%
04/30/2018
100,051
0.26%
0
0.22%
07/31/2018
Source Markets Plc - S&P 500 UCITS ETF
55,890
0.15%
55,890
0.01%
06/29/2018
R Mid Cap Euro
54,806
0.14%
-17,500
0.76%
07/31/2018
Cartera Emporda 2000, SICAV
49,973
0.13%
13,367
6.1%
12/31/2017
| Address |
Gaston Geenslaan 1
Leuven VL 3001
Belgium
|
|
Employees
|
- |
| Website |
http://www.oxurion.com |
| Updated |
07/08/2019 |
| ThromboGenics NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA (ocriplasmin) brand name. The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium. |
